Show simple item record

dc.contributor.authorPaplomata, E
dc.contributor.authorBachelot, T
dc.contributor.authorMueller, V
dc.contributor.authorMurias, C
dc.contributor.authorMurthy, RK
dc.contributor.authorOkines, AFC
dc.contributor.authorWardley, Andrew M
dc.contributor.authorWalker, LN
dc.contributor.authorOliveira, AMAD
dc.date.accessioned2019-10-04T09:48:23Z
dc.date.available2019-10-04T09:48:23Z
dc.date.issued2019en
dc.identifier.citationPaplomata E, Bachelot T, Mueller V, Murias C, Murthy RK, Okines AFC, et al. 198TiP A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB). Ann Oncol. 2019;30(Supplement_3):63-4.en
dc.identifier.doi10.1093/annonc/mdz100.049en
dc.identifier.urihttp://hdl.handle.net/10541/622097
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdz100.049en
dc.titleA randomized, double-blinded, controlled study of tucatinib (ONT-380) vs placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentDepartment of Hematology and Medical Oncology, Emory Winship Cancer Institute Atlanta, GA,en
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2020-04-20T13:39:01Z


Files in this item

Thumbnail
Name:
561991.pdf
Size:
58.21Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record